<i>Neisseria meningitidis</i>Serogroup X in Sub-Saharan Africa

Agnememel, Alain; Hong, Eva; Giorgini, Dario; Núñez-Samudio, Virginia; Deghmane, Ala‐Eddine; Taha, Muhamed‐Kheir

doi:10.3201/eid2204.150653

Cited by 29 publications

(25 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…14,15,21 Since the 1990s, isolates of serogroup X have been reported in several countries within the meningitis belt. 22 Recently, an increase in serogroup Y invasive meningococcal disease in some European countries was reported based on the epidemiological data. 23 As the epidemiology and distribution of these disease-causing pathogens as well as serogroups varies widely by geographic region and show time patterns since 2005 we have been performing a hospital-based meningitis surveillance study across several regions of Turkey.…”

Section: Introductionmentioning

confidence: 99%

Bacterial agents causing meningitis during 2013–2014 in Turkey: A multi-center hospital-based prospective surveillance study

Ceyhan

Özsürekçi

Gürler

et al. 2016

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

This is an observational epidemiological study to describe causes of bacterial meningitis among persons between 1 month and 18 y of age who are hospitalized with suspected bacterial meningitis in 7 Turkish regions. covering 32% of the entire population of Turkey. We present here the results from 2013 and 2014. A clinical case with meningitis was defined according to followings: any sign of meningitis including fever, vomiting, headache, and meningeal irritation in children above one year of age and fever without any documented source, impaired consciousness, prostration and seizures in those < 1 y of age. Single tube multiplex PCR assay was performed for the simultaneous identification of bacterial agents. The specific gene targets were ctrA, bex, and ply for N. meningitidis, Hib, and S. pneumoniae, respectively. PCR positive samples were recorded as laboratory-confirmed acute bacterial meningitis. A total of 665 children were hospitalized for suspected acute meningitis. The annual incidences of acute laboratory-confirmed bacterial meningitis were 0.3 cases / 100,000 population in 2013 and 0.9 cases/100,000 in 2014. Of the 94 diagnosed cases of bacterial meningitis by PCR, 85 (90.4%) were meningococcal and 9 (9.6%) were pneumococcal. Hib was not detected in any of the patients. Among meningococcal meningitis, cases of serogroup Y, A, B and W-135 were 2.4% (n = 2), 3.5% (n = 3), 32.9% (n = 28), and 42.4% (n = 36). No serogroup C was detected among meningococcal cases. Successful vaccination policies for protection from bacterial meningitis are dependent on accurate determination of the etiology of bacterial meningitis. Additionally, the epidemiology of meningococcal disease is dynamic and close monitoring of serogroup distribution is comprehensively needed to assess the benefit of adding meningococcal vaccines to the routine immunization program.

show abstract

Section: Introductionmentioning

confidence: 99%

Bacterial agents causing meningitis during 2013–2014 in Turkey: A multi-center hospital-based prospective surveillance study

Ceyhan

Özsürekçi

Gürler

et al. 2016

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…21,22 Serogroup X MD (MenX) emerged in Africa in the 1990s, reaching epidemic levels in Niger in 2006. 23 Cases of MenX isolates related to those responsible for meningococcal outbreaks in Niger, Togo and Burkina Faso have recently been recorded in Northern Italy among African and Bangladeshi migrants living in refugee camps. 14 MenW has been known since the 1980s; however, its emergence as an epidemic serogroup was reported in 2000, in Hajj pilgrims returning to France and the UK.…”

Section: Review Of the Global Incidence And Epidemiology Of Meningocomentioning

confidence: 99%

Meningococcal disease and control in China: Findings and updates from the Global Meningococcal Initiative (GMI)

Shao

Liu

et al. 2018

Journal of Infection

Self Cite

View full text Add to dashboard Cite

The Global Meningococcal Initiative (GMI) is a global expert group, including scientists, clinicians and public health officials from a wide range of specialities. The goal of the GMI is to prevent meningococcal disease worldwide through education, research, and co-operation. The Chinese GMI roundtable meeting was held in June 2017. The GMI met with local experts to gain insight into the meningococcal disease burden in China and current prevention and vaccination strategies in place. China experienced five epidemics of serogroup A meningococcal disease (MenA) between 1938 and 1977, with peak incidence of 403/100,000 recorded in 1967. MenA incidence rates have significantly declined following the universal introduction of the MenA polysaccharide vaccine in China in the 1980s. Further, surveillance data indicates changing meningococcal epidemiology in China with the emergence of new clones of serogroup B from serogroup C clonal complex (cc) 4821 due to capsular switching, and the international spread of serogroup W cc11. The importance of carriage and herd protection for controlling meningococcal disease was highlighted with the view to introduce conjugate vaccines and serogroup B vaccines into the national immunization schedule. Improved disease surveillance and standardized laboratory techniques across and within provinces will ensure optimal epidemiological monitoring.

show abstract

“…The epidemiology of serogroup X in Africa has been partially described. 17 Furthermore, analyses showed that the infecting strains belonged to a new sequence type, ST-5403 (clonal complex unnasigned), in Kenya, and ST-181 (ST-181 complex), a sequence type yet found in Chad, Mali, 6 and Niger. The sequence type and clonal complex of our isolate (ST-5799; ST-22 complex) were unrelated to previously described African serogroup X isolates.…”

Section: Discussionmentioning

confidence: 99%

Neisseria meningitidisSerogroup X ST-5799 (ST-22 complex) in Turkey: A unique pediatric case

Tanır

Özsürekçi

Lucidarme

et al. 2017

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Although outbreaks of Neisseria meningitidis serogroup X occured in a couple of African countries, a limited number of serogroup X meningococcal cases were reported in America and Europe as well as Turkey. Additionally, serogroup X is still not represented in current conjugated meningococcal vaccines. Here, we describe the first pediatric case with meningitis caused by Neisseria meningitidis serogroup X ST-5799 (ST-22 complex) that formed a distinct lineage.

show abstract

Neisseria meningitidisSerogroup X in Sub-Saharan Africa

Cited by 29 publications

References 12 publications

Bacterial agents causing meningitis during 2013–2014 in Turkey: A multi-center hospital-based prospective surveillance study

Bacterial agents causing meningitis during 2013–2014 in Turkey: A multi-center hospital-based prospective surveillance study

Meningococcal disease and control in China: Findings and updates from the Global Meningococcal Initiative (GMI)

Neisseria meningitidisSerogroup X ST-5799 (ST-22 complex) in Turkey: A unique pediatric case

Contact Info

Product

Resources

About